Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03881488 · ClinicalTrials.gov registry record · Phase 1
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
A Phase 1 study, sponsored by Compass Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT03881488 is a Phase 1 study that has completed, run by Compass Therapeutics. The registered enrollment target is 100 participants.
The verdict
NCT03881488, a Phase 1 study, has completed, sponsored by Compass Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Interventions
- DRUG Pembrolizumab (KEYTRUDA®)
- DRUG CTX-471
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-05-17 |
| Est. Completion | 2025-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03881488
The ClinicalTrials.gov registry entry for NCT03881488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Compass Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab (KEYTRUDA®) is the first listed.
NCT03881488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03881488 about?
NCT03881488 is a clinical study titled "Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies". This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 tr...
What is the current status of trial NCT03881488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2019-05-17. Estimated completion is 2025-05-21.
What interventions are being tested in trial NCT03881488?
The interventions under investigation include: Pembrolizumab (KEYTRUDA®) (DRUG), CTX-471 (DRUG).
Who is sponsoring clinical trial NCT03881488?
This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.